open access

Vol 21, No 2 (2017)
Artykuły redakcyjne
Published online: 2017-06-30
Get Citation

Can hypertensive therapy reduce the risk of cognitive impairment and dementia?

Krystyna Widecka
DOI: 10.5603/AH.2017.0008
·
Arterial Hypertension 2017;21(2):61-68.

open access

Vol 21, No 2 (2017)
Artykuły redakcyjne
Published online: 2017-06-30

Abstract

Hypertension is an important risk factor for cardiovascular diseases and dementia. The efficacy of antihypertensive therapy, however, is still insufficient. Combination therapy of hypertension at least two drugs achieves the target blood pressure. The combination of perindopril and amlodipine is extensively studied well the combination of drugs, for which demonstrated a reduction in total mortality and cardiovascular events and stroke.

The review explores molecular and clinical studies that might help explain the relation between the renin-angiotensin system, hypertension, and dementia and whether treatment with ACE inhibitor (perindopril) and CCB (amlodipine) have a part to play in the management of the disease.

Abstract

Hypertension is an important risk factor for cardiovascular diseases and dementia. The efficacy of antihypertensive therapy, however, is still insufficient. Combination therapy of hypertension at least two drugs achieves the target blood pressure. The combination of perindopril and amlodipine is extensively studied well the combination of drugs, for which demonstrated a reduction in total mortality and cardiovascular events and stroke.

The review explores molecular and clinical studies that might help explain the relation between the renin-angiotensin system, hypertension, and dementia and whether treatment with ACE inhibitor (perindopril) and CCB (amlodipine) have a part to play in the management of the disease.

Get Citation

Keywords

perindopril/amlodypina, essential hypertension, cardioprotection, dementia, Alzheimer’s disease

About this article
Title

Can hypertensive therapy reduce the risk of cognitive impairment and dementia?

Journal

Arterial Hypertension

Issue

Vol 21, No 2 (2017)

Pages

61-68

Published online

2017-06-30

DOI

10.5603/AH.2017.0008

Bibliographic record

Arterial Hypertension 2017;21(2):61-68.

Keywords

perindopril/amlodypina
essential hypertension
cardioprotection
dementia
Alzheimer’s disease

Authors

Krystyna Widecka

References (51)
  1. Zdrojewski Ł, Zdrojewski T, Rutkowski M, et al. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol. 2013; 71(4): 381–392.
  2. Zdrojewski T, Szpakowski P, Bandosz P, et al. Arterial hypertension in Poland in 2002. J Hum Hypertens. 2004; 18(8): 557–562.
  3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28): 2159–2219.
  4. Tykarski A, Narkiewicz K, Gaciong Z, et al. Guidelines for the Management of Hypertension. Arterial Hypertension. 2015; 19(2): 53–83.
  5. Drygas W, Niklas AA, Piwońska A, et al. Multi-centre National Population Health Examination Survey (WOBASZ II study): assumptions, methods, and implementation. Kardiol Pol. 2016; 74(7): 681–690.
  6. Ivan CS, Seshadri S, Beiser A, et al. Dementia after stroke: the Framingham Study. Stroke. 2004; 35(6): 1264–1268.
  7. Wong TY, Klein R, Sharrett AR, et al. Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities Study. Stroke. 2002; 33(6): 1487–1492.
  8. Dahlof B, et al. Ascot Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895–906.
  9. Williams B, Lacy PS, Thom SM. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Circulation. 2006; 113(9): 1213–1225.
  10. Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006; 113(9): 1213–1225.
  11. Simone Gde, Devereux R, Chinali M, et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. Journal of Hypertension. 2010; 28(2): 353–360.
  12. Zhang Yi, Ly C, Yannoutsos A, et al. Effect of a fixed combination of Perindopril and Amlodipine on blood pressure control in 6256 patients with not-at-goal hypertension: the AVANT'AGE study. J Am Soc Hypertens. 2013; 7(2): 163–169.
  13. Nagy VL. Twenty-four-hour ambulatory blood pressure reduction with a perindopril/amlodipine fixed-dose combination. Clin Drug Investig. 2013; 33(7): 469–476.
  14. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet. 2003; 362(9386): 782–788.
  15. Bertrand ME, Ferrari R, Remme WJ, et al. EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010; 159(5): 795–802.
  16. Asmar R, Topouchian J, Pannier B, et al. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior® study. Journal of Hypertension. 2001; 19(4): 813–818.
  17. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens. 2002; 15(4 Pt 1): 316–320.
  18. Matsumoto T, Minai K, Horie H, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. Journal of the American College of Cardiology. 2003; 41(8): 1373–1379.
  19. Sacco RL, Adams R, Albers GI, et al. Albers G. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for healthcare professionals from the American Heart Association/American Association Council on . Stroke. 2006; 37: 577–617.
  20. Baumgart M, Snyder HM, Carrillo MC, et al. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement. 2015; 11(6): 718–726.
  21. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996; 347(9009): 1141–1145.
  22. Birns J, Morris R, Donaldson N, et al. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens. 2006; 24(10): 1907–1914.
  23. Elias PK, Elias MF, Robbins MA, et al. Blood pressure-related cognitive decline: does age make a difference? Hypertension. 2004; 44(5): 631–636.
  24. Cuadra AE, Shan Z, Sumners C, et al. A current view of brain renin-angiotensin system: Is the (pro)renin receptor the missing link? Pharmacol Ther. 2010; 125(1): 27–38.
  25. Xia H, Lazartigues E. Angiotensin-converting enzyme 2: central regulator for cardiovascular function. Curr Hypertens Rep. 2010; 12(3): 170–175.
  26. Wright JW, Harding JW. Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res Brain Res Rev. 1997; 25(1): 96–124.
  27. Stragier B, De Bundel D, Sarre S, et al. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail Rev. 2008; 13(3): 321–337.
  28. Cesari M, Rossi GP, Pessina AC. Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. J Hypertens. 2002; 20(5): 793–799.
  29. Inaba S, Iwai M, Furuno M, et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension. 2009; 53(2): 356–362.
  30. Kölsch H, Jessen F, Freymann N, et al. ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia. Neurosci Lett. 2005; 377(1): 37–39.
  31. Miners JS, Ashby E, Van Helmond Z, et al. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2008; 34(2): 181–193.
  32. Savaskan E, Hock C, Olivieri G, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging. 2001; 22(4): 541–546.
  33. Albiston AL, McDowall SG, Matsacos D, et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem. 2001; 276(52): 48623–48626.
  34. Yamada K, Horita T, Takayama M, et al. Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res. 2011; 1421: 110–120.
  35. Yamada K, Uchida S, Takahashi S, et al. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res. 2010; 1352: 176–186.
  36. Braszko JJ. Participation of D 1-4 dopamine receptors in the pro-cognitive effects of angiotensin IV and des-Phe 6 angiotensin IV. Neurosci Biobehav Rev. 2010; 34(3): 343–350.
  37. Braszko JJ. (+)-UH 232, a partial agonist of the D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe(6)-angiotensin IV in rats. Eur Neuropsychopharmacol. 2010; 20(4): 218–225.
  38. Gard PR, Olivier G, Golding B, et al. Assessment of biological activity of novel peptide analogues of angiotensin IV. J Pharm Pharmacol. 2011; 63(4): 565–571.
  39. Hanes DS, Weir MR. Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. Am J Geriatr Cardiol. 2007; 16(3): 175–182.
  40. Barnes NM, Cheng CH, Costall B, et al. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol. 1991; 200(2-3): 289–292.
  41. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol. 2007; 6(4): 373–378.
  42. Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Archives of Internal Medicine. 2003; 163(9): 1069.
  43. Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis. 2010; 20(3): 903–914.
  44. Fransen M, Anderson C, Chalmers J, et al. PROGRESS. Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial. Stroke. 2003; 34(10): 2333–2338.
  45. Ohrui T, Matsui T, Yamaya M, et al. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc. 2004; 52(4): 649–650.
  46. Ohrui T, Tomita N, Sato-Nakagawa T, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004; 63(7): 1324–1325.
  47. Miners JS, Van Helmond Z, Chalmers K, et al. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2006; 65(10): 1012–1021.
  48. Toescu EC, Verkhratsky A, Landfield PW. Ca2+ regulation and gene expression in normal brain aging. Trends Neurosci. 2004; 27(10): 614–620.
  49. Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ. 1999; 161(5): 501–506.
  50. Forette F, Seux ML, Staessen JA, et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002; 162(18): 2046–2052.
  51. Peters R, Collerton J, Granic A, et al. Antihypertensive drug use and risk of cognitive decline in the very old: an observational study - the Newcastle 85+ Study. J Hypertens. 2015; 33(10): 2156–2164.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl